^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    VEGF-B inhibitor

    Related drugs:
    6d
    VEGF-B: A multifaceted modulator with emerging therapeutic applications. (PubMed, Pharmacol Res)
    However, clinical translation remains challenging, as exemplified by the recent failure of the anti-VEGF-B antibody CSL346 in diabetic kidney disease, underscoring our incomplete understanding of VEGF-B biology. This review integrates cutting-edge insights into the diverse functions of VEGF-B, proposes a mechanistic framework for its complex signaling networks, and outlines a roadmap for developing precision therapies for metabolic, cardiovascular, neurodegenerative, and oncological diseases. We address the critical translational challenges to maximize the therapeutic benefits while preserving the crucial homeostatic functions of VEGF-B.
    Review • Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1) • VEGFA (Vascular endothelial growth factor A) • FLT1 (Fms-related tyrosine kinase 1) • VEGFB (Vascular Endothelial Growth Factor B) • NRP1 (Neuropilin 1)
    9d
    An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer (clinicaltrials.gov)
    P1, N=8, Completed, Precision Biotech Taiwan Corp.
    New P1 trial
    |
    Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • gefitinib • PB101
    3ms
    Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma (clinicaltrials.gov)
    P2, N=3, Terminated, Sidney Kimmel Cancer Center at Thomas Jefferson University | Completed --> Terminated; Slow accrual
    Trial termination
    |
    Zaltrap (ziv-aflibercept IV)
    3ms
    4D-150 in Patients With Diabetic Macular Edema (clinicaltrials.gov)
    P2, N=72, Active, not recruiting, 4D Molecular Therapeutics | Recruiting --> Active, not recruiting | Trial completion date: Jul 2028 --> Feb 2029 | Trial primary completion date: Feb 2028 --> Feb 2029
    Enrollment closed • Trial completion date • Trial primary completion date
    5ms
    4FRONT-2: Single Intravitreal Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration (clinicaltrials.gov)
    P3, N=400, Recruiting, 4D Molecular Therapeutics
    New P3 trial
    6ms
    PRISM: 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration (clinicaltrials.gov)
    P1/2, N=215, Recruiting, 4D Molecular Therapeutics | Trial completion date: Nov 2026 --> Jan 2031 | Trial primary completion date: Nov 2025 --> Mar 2027
    Trial completion date • Trial primary completion date
    10ms
    4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration (clinicaltrials.gov)
    P3, N=400, Recruiting, 4D Molecular Therapeutics
    New P3 trial
    12ms
    A novel electrochemical immunosensor for the ultrasensitive detection of vascular endothelial growth factor based on MB@Cu-MOFs/MWCNTs composite. (PubMed, Mikrochim Acta)
    Additionally, the electrochemical immunosensor presented commendable selectivity, availability, and reproducibility, along with an effective capacity for detecting VEGF165 in clinical samples. Consequently, the immunosensor is expected to revolutionize early screening for VEGF165-related diseases, which offer a promising, cost-effective, and precise diagnostic tool for clinical utility.
    Journal
    |
    VEGFA (Vascular endothelial growth factor A)
    1year
    Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (clinicaltrials.gov)
    P1, N=78, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    CD8 (cluster of differentiation 8) • HGF (Hepatocyte growth factor) • CTAG1B (Cancer/testis antigen 1B) • CD4 (CD4 Molecule) • FGF (Fibroblast Growth Factor) • MLANA (Melan-A)
    |
    Keytruda (pembrolizumab) • Zaltrap (ziv-aflibercept IV)
    1year
    PRISM: 4D-150 in Patients with Neovascular (Wet) Age-Related Macular Degeneration (clinicaltrials.gov)
    P1/2, N=215, Recruiting, 4D Molecular Therapeutics | N=150 --> 215 | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2024 --> Nov 2025
    Enrollment change • Trial completion date • Trial primary completion date • Gene therapy
    1year
    Electrochemical sensor for vascular endothelial growth factor based on self-assembling DNA aptamer structure. (PubMed, Sci Total Environ)
    The interaction behaviour between VEGF in the solution and the immobilise DNA aptamer/Ppy-based structure was analysed using Langmuir isotherm model. The developed electrochemical biosensor in promising for in vitro applications in early cancer diagnostics and treatment monitoring, enabling rapid screening of patient samples.
    Journal
    |
    VEGFA (Vascular endothelial growth factor A)
    over1year
    Screening of herbal extracts binding with vascular endothelial growth factor by applying HerboChip platform. (PubMed, Chin Med)
    The current results demonstrated the applicability of the HerboChip platform and systematically elucidated the activity of selected TCMs on angiogenesis and its related signal transduction mechanisms.
    Journal
    |
    VEGFA (Vascular endothelial growth factor A) • NOS3 (Nitric oxide synthase 3)